Drug intelligence / Profile preview

RK008

Development stage: Preclinical
Lead developer: RevolKa
Modality: Recombinant Proteins and Enzymes

Overview

RK008 is a protein-based therapeutic candidate currently under development by RevolKa. It was engineered using RevolKa's proprietary aiProtein platform, which combines artificial intelligence with directed evolution to optimize protein properties such as stability, binding affinity, and biological activity. While the specific molecular target and therapeutic indication for RK008 have not been publicly disclosed by the company, the candidate has completed an undisclosed early stage of development.

Beyond the preview

Go deeper on RK008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RK008.

Explore the full profile